Clinical Trial Update: 3-AP Plus Cisplatin in Treating Patients With Recurrent or Metastatic Adenocarcinoma of the Esophagus or Gastroesophageal Junction [Phase 2]

View source ↗

Summary

This update reports the completion of a Phase 2 trial evaluating 3-AP (Triapine) plus cisplatin in patients with recurrent or metastatic adenocarcinoma of the e…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenocarcinoma of the Esophagus
• Esophageal Cancer
• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• 3-AP
• CISPLATIN (cisplatin)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Adenocarcinoma of the Esophagus, Recurrent Esophageal Cancer | Phase 2 | Status: COMPLETED